At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
QuickShot™ - 50 mg Treatment B +2 moredrug
Likely dose
QuickShot™ - 50 mg Treatment Bfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
3 Arm Open-label Randomized Multidose Study of Pharmacokinetics, Safety & Tolerability of Testosterone Enanthate Administered Subcutaneously Via an Auto-injector Device or Intramuscular Testosterone Enanthate in Hypogonadal Adult Males
In Brief
A Phase 2 clinical trial evaluating QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, and 1 other intervention for Hypogonadism. Completed, enrolled 39 participants across 1 site.
Detailed Summary
Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartSep 2013
Primary CompletionJan 2014
TodayJul 2026
First PostedJun 26, 2013
Enrollment StartSep 1, 2013
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.0 years ago
Interventions
QuickShot™ - 50 mg Treatment Bdrug
QuickShot™ for the delivery of testosterone
QuickShot™ - 100 mg Treatment Adrug
QuickShot™ for the delivery of testosterone
Delatestryl 200 mg IM Treatment Cdrug
Standard of care